Press Releases

BrainStorm Cell Therapeutics' Chief Scientific Advisor to Present At The 2015 FENS-RM in Thessaloniki, Greece

HACKENSACK, N.J. and PETACH TIKVAH, Israel, Oct. 8, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announces that its Chief Scientific Advisor, Prof Daniel Offen, PhD, will be presenting today at the 2015 Federation Of European Neuroscience Societies (FENS) Regional Meeting, in Thessaloniki, Greece.

BrainStorm Cell Therapeutics

The Federation of European Neuroscience Societies (FENS) is a main organisation for neuroscience in Europe, and it is currently representing 42 European national and mono-disciplinary neuroscience societies with close to 23,000 member scientists from 32 European countries.


FFRM 2015 (symposium entitled: Targeting Neurodegenerative     

Disease: from Bench to bedside)


15:15 – 16:55, Room 2


Thursday, October 8, 2015


Loannis Vellidis Congress Center, Thessaloniki, Greece

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn® has been administered to over 60 patients with ALS in clinical trials conducted in Israel and the United States, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.  For more information, visit the company's website at

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements.  The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at  These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements.  These forward-looking statements are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.




Uri Yablonka                          

Michael Rice

Chief Operating Officer             

LifeSci Advisors, LLC

BrainStorm Cell Therapeutics Inc.   


US Office: 201-488-0460          

Israeli Office: +972-3-9236384

Logo -

To view the original version on PR Newswire, visit:

SOURCE BrainStorm Cell Therapeutics Inc.

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds